|
|
Article: Hybridon's Second-Generation Immunomodulatory Oligonucleotides Prevent Development of Allergic Asthma in Mouse Models in Preclinical Studies.
- Article from:
- PR Newswire
- Article date:
- September 11, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Hybridon, Inc. (BULLETIN BOARD: HYBN.OB) announced the presentation of preclinical data from studies of its second-generation immunomodulatory oligonucleotides (IMOTM) in mouse models of allergic asthma. The presentation will be made today during the Asthma Therapy II session from 3:45 to 5:15 p.m. at the World Allergy Organization Congress -- XVIII ICACI being held in Vancouver, BC, Canada. The oral presentation entitled: "Novel immunomodulatory oligonucleotides (IMOs) prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma" will be given by Dr. D.K. Agrawal of the Creighton University School of Medicine, Omaha, NE. The co-authors ...